AZN

阿斯利康
NYSE

实时行情|Nasdaq Last Sale

47.57
+0.49
+1.04%
盘后: 47.57 0 0.00% 16:11 02/26 EST
开盘
47.52
昨收
47.08
最高
47.98
最低
47.27
成交量
390.03万
成交额
--
52周最高
51.55
52周最低
36.83
市值
1,248.37亿
市盈率(TTM)
92.08
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测AZN价格均价为53.05,最高价位57.00,最低价为48.50。

EPS

AZN 新闻

更多
  • What Happens With AbbVie If Its Allergan Buyout Is Blocked?
  • MotleyFool.com · 13小时前
  • Should You Buy Inovio Pharmaceuticals Stock Right Now?
  • MotleyFool.com · 13小时前
  • 18 Medical Stocks To Watch Amid The Coronavirus Outbreak
  • Benzinga · 1天前
  • 18 Medical Stocks To Watch Amid The Coronavirus Outbreak
  • Benzinga · 1天前

所属板块

制药
+0.02%
制药与医学研究
+0.42%

热门股票

代码
价格
涨跌幅
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

AZN 简况

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.
展开

微牛提供AstraZeneca plc (ADR)(NYSE-AZN)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的AZN股票新闻,以帮助您做出投资决策。